within Pharmacolibrary.Drugs.R_RespiratorySystem.R05D_CoughSuppressantsExclCombinationsWithExpectorants.R05DB12_BibenzoniumBromide;

model BibenzoniumBromide
  extends Pharmacolibrary.Drugs.ATC.R.R05DB12;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>R05DB12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bibenzonium bromide is a quaternary ammonium compound classified as an antitussive, used for the treatment of cough. It acts as a peripheral antitussive agent, likely by suppressing the cough reflex through local action in the respiratory tract. It is not widely approved or currently used in most countries.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data for bibenzonium bromide in humans was found. The following parameters are rough estimates based on related quaternary ammonium antitussives.</p><h4>References</h4><ol><li><p>Tytgat, GN (2007). Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. <i>Drugs</i> 67(9) 1343–1357. DOI:<a href=\"https://doi.org/10.2165/00003495-200767090-00007\">10.2165/00003495-200767090-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17547475/\">https://pubmed.ncbi.nlm.nih.gov/17547475</a></p></li><li><p>Quast, TA, et al., &amp; Edwards, SH (2015). Pharmacokinetics of bromide in adult sheep following oral and intravenous administration. <i>Australian veterinary journal</i> 93(1-2) 20–25. DOI:<a href=\"https://doi.org/10.1111/avj.12285\">10.1111/avj.12285</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25622704/\">https://pubmed.ncbi.nlm.nih.gov/25622704</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end BibenzoniumBromide;
